Image Place holder

Kosj Yamoah, MD, PhD

Academic Rank: Assistant Member

Overview

Dr. Yamoah is committed to increasing access and quality of care among the minority population, particularly men of African descent.


Discipline

    • Radiation Oncology
    • Cancer Epidemiology
    • Cancer Epidemiology Program

Education & Training

Fellowship:

  • Atlantic Health, New Jersey, Internship - Internship
  • Korle Bu Teaching Hospital, Visiting Resident - Radiation Oncology Research
  • St. Jude Children's Research Hospital, Visiting Resident - Pediatric Radiation Oncology
  • Washington University, Visiting Resident - Gynecologic Brachytherapy
  • Thomas Jefferson University Hospital, Chief Resident - Radiation Oncology
  • Mount Sinai Graduate School of Biological Sciences & Memorial Sloan-Kettering Cancer Center, PhD - Oncological Science
  • Mount Sinai School of Medicine, MD -
  • University of Pennsylvania, Research Fellow - Molecular Epidemiology, Department of Epidemiology and Population Sciences
Research

Dr. Yamoah is a physician scientist who is highly demanded in the fast growing field of prostate cancer disparities research. He has won several awards and honors and is a respected member of the scientific community. Dr. Yamoah’s research focus is on the biologic factors that predispose African American men to higher prostate cancer incidence and mortality; he will use his research findings to inform targeted treatment recommendations in the clinical setting. Currently he is pursuing translational research to identify gene-specific factors associated with health disparities of aggressive prostate cancer as well as poor progression-free survival in African Americans. He has had the opportunity to present research at national meetings and authored 25 peer-reviewed publications.

Publications

  • Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, Kwok Y, Seider MJ, Hsu IC, Hartford AC, Horwitz EM, Yamoah K, Jones CU, Michalski JM, Lee WR, Pisansky TM, Rabinovitch R, Rotman M, Pryzant RM, Kim HE, Thomas CR, Shipley WU, Sandler HM. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol. 2018 Oct. Pubmedid: 30316827.
  • Berglund AE, Rounbehler RJ, Gerke T, Awasthi S, Cheng CH, Takhar M, Davicioni E, Alshalalfa M, Erho N, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Trock BJ, Den RB, Cleveland JL, Park JY, Dhillon J, Yamoah K. Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer. Prostate Cancer P D. 2018 Oct. Pubmedid: 30367117.
  • Rounbehler RJ, Berglund AE, Gerke T, Takhar MM, Awasthi S, Li W, Davicioni E, Erho NG, Ross AE, Schaeffer EM, Klein EA, Karnes RJ, Jenkins RB, Cleveland JL, Park JY, Yamoah K. Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2018 Nov;27(11):1376-1383. Pubmedid: 30108099. Pmcid: PMC6214732.
  • Awasthi S, Gerke T, Park JY, Asamoah FA, Williams VL, Fink AK, Balkrishnan R, Lee DI, Malkowicz SB, Lal P, Dhillon J, Pow-Sang JM, Rebbeck TR, Yamoah K. Optimizing Time-to-Treatment to achieve durable biochemical disease control after surgery in prostate cancer - A multi-institutional cohort study. Cancer Epidemiol Biomarkers Prev. 2018 Nov. Pubmedid: 30413401.
  • Williams VL, Awasthi S, Fink AK, Pow-Sang JM, Park JY, Gerke T, Yamoah K. African-American men and prostate cancer-specific mortality: a competing risk analysis of a large institutional cohort, 1989-2015. Cancer Med. 2018 May;7(5):2160-2171. Pubmedid: 29601662. Pmcid: PMC5943433.
  • Asamoah FA, Yarney J, Awasthi S, Vanderpuye V, Venkat PS, Fink AK, Naghavi AO, Abrahams A, Mensah JE, Sasu E, Tagoe SNA, Johnstone PAS, Yamoah K. Contemporary Radiation Treatment of Prostate Cancer in Africa: A Ghanaian Experience. J Glob Oncol. 2018 Jul;(4):1-13. Pubmedid: 30085846.
  • Echevarria MI, Naghavi AO, Abuodeh YA, Ahmed KA, Chevere C, Fernandez D, Yamoah K. Low-dose-rate Brachytherapy for Prostate Cancer in Low-resource Settings. Int J Radiat Oncol Biol Phys. 2017 Oct;99(2):378-382. Pubmedid: 28871987.
  • Luu HN, Lin HY, Sørensen KD, Ogunwobi OO, Kumar N, Chornokur G, Phelan C, Jones D, Kidd L, Batra J, Yamoah K, Berglund A, Rounbehler RJ, Yang M, Lee SH, Kang N, Kim SJ, Park JY, Di Pietro G. miRNAs associated with prostate cancer risk and progression. BMC Urol. 2017 Mar;17(1):18. Pubmedid: 28320379. Pmcid: PMC5359825.
  • Kim H, Kalchman I, Santiago-Jiménez M, Lehrer J, Guo J, Hermann G, Yamoah K, Alshalalfa M, Huang HC, Ross AE, Schaeffer EM, Davicioni E, Erho N, Yousefi K, Den RB. Transcriptome evaluation of the relation between body mass index and prostate cancer outcomes. Cancer. 2017 Jun;123(12):2240-2247. Pubmedid: 28140459.
  • Jeffers A, Sochat V, Kattan MW, Yu C, Melcon E, Yamoah K, Rebbeck TR, Whittemore AS. Predicting Prostate Cancer Recurrence After Radical Prostatectomy. Prostate. 2017 Feb;77(3):291-298. Pubmedid: 27775165. Pmcid: PMC5877452.
  • Yamoah K, Johnstone PA. Proton beam therapy: clinical utility and current status in prostate cancer. Onco Targets Ther. 2016 Sep;9:5721-5727. Pubmedid: 27695349. Pmcid: PMC5033502.
  • Naghavi AO, Echevarria M, Strom T, Abuodeh YA, Ahmed KA, Venkat PS, Trotti A, Harrison LB, Green BL, Yamoah K, Caudell JJ. Race Is Associated With Poor Outcomes in Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2S):E407. Pubmedid: 27674609.
  • Echevarria MI, Naghavi AO, Venkat PS, Abuodeh YA, Chevere C, Yamoah K. The impact of body mass index on dosimetric quality in low-dose-rate prostate brachytherapy. J Contemp Brachytherapy. 2016 Oct;8(5):386-390. Pubmedid: 27895679. Pmcid: PMC5116453.
  • Naghavi AO, Echevarria MI, Grass GD, Strom TJ, Abuodeh YA, Ahmed KA, Kim Y, Trotti AM, Harrison LB, Yamoah K, Caudell JJ. Having Medicaid insurance negatively impacts outcomes in patients with head and neck malignancies. Cancer. 2016 Nov;122(22):3529-3537. Pubmedid: 27479362.
  • Yamoah K, Zeigler-Johnson CM, Jeffers A, Malkowicz B, Spangler E, Park JY, Whittemore A, Rebbeck TR. The impact of body mass index on treatment outcomes for patients with low-intermediate risk prostate cancer. BMC Cancer. 2016 Jul;16:557. Pubmedid: 27473687. Pmcid: PMC4966583.
  • Naghavi AO, Echevarria MI, Strom TJ, Abuodeh YA, Ahmed KA, Venkat PS, Trotti A, Harrison LB, Green BL, Yamoah K, Caudell JJ. Treatment delays, race, and outcomes in head and neck cancer. Cancer Epidemiol. 2016 Dec;45:18-25. Pubmedid: 27664388.
  • Palmer JD, Siglin J, Yamoah K, Dan T, Champ CE, Bar-Ad V, Werner-Wasik M, Evans JJ, Kim L, Glass J, Farrell C, Andrews DW, Shi W. Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better. J Neurooncol. 2015 Sep;124(2):215-221. Pubmedid: 26024653.
  • Yamoah K, Johnson MH, Choeurng V, Faisal FA, Yousefi K, Haddad Z, Ross AE, Alshalafa M, Den R, Lal P, Feldman M, Dicker AP, Klein EA, Davicioni E, Rebbeck TR, Schaeffer EM. Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer. J Clin Oncol. 2015 Sep;33(25):2789-2796. Pubmedid: 26195723. Pmcid: PMC4550692.
  • Yamoah K, Showalter TN, Ohri N. Radiation Therapy Intensification for Solid Tumors: A Systematic Review of Randomized Trials. Int J Radiat Oncol Biol Phys. 2015 Nov;93(4):737-745. Pubmedid: 26530740. Pmcid: PMC4635974.
  • Eldredge-Hindy HB, Duffy D, Yamoah K, Simone NL, Skowronski J, Dicker AP, Anne PR. Modeled risk of ischemic heart disease following left breast irradiation with deep inspiration breath hold. Pract Radiat Oncol. 2015 May;5(3):162-168. Pubmedid: 25957186.
  • Grover S, Balogun OD, Yamoah K, Groen R, Shah M, Rodin D, Martei Y, Olson AC, Slone JS, Shulman LN, Coleman CN, Hahn SM. Corrigendum: "Training Global Oncologists: Addressing the Global Cancer Control Problem". Front Oncol. 2015 Jun;5:133. Pubmedid: 26114095. Pmcid: PMC4461853.
  • Yamoah K, Deville C, Vapiwala N, Spangler E, Zeigler-Johnson CM, Malkowicz B, Lee DI, Kattan M, Dicker AP, Rebbeck TR. African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men. Urol Oncol. 2015 Feb;33(2):70.e15-70.e22. Pubmedid: 25304288. Pmcid: PMC4980822.
  • Grover S, Balogun OD, Yamoah K, Groen R, Shah M, Rodin D, Olson AC, Slone JS, Shulman LN, Coleman CN, Hahn SM. Training global oncologists: addressing the global cancer control problem. Front Oncol. 2015 Apr;5:80. Pubmedid: 25905040. Pmcid: PMC4389376.
  • Yamoah K, Walker A, Spangler E, Zeigler-Johnson CM, Malkowicz B, Lee DI, Dicker AP, Rebbeck TR, Lal P. African-american race is a predictor of seminal vesicle invasion after radical prostatectomy. Clin Genitourin Cancer. 2015 Apr;13(2):e65-e72. Pubmedid: 25450037. Pmcid: PMC4980819.
  • Yamoah K, Eldredge-Hindy HB, Zaorsky NG, Palmer JD, Doyle LA, Sendecki JA, Hesney AA, Harper L, Repka M, Showalter TN, Hurwitz MD, Dicker AP, Den RB. Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma. Brachytherapy. 2014 Oct;13(5):456-464. Pubmedid: 24953945.
  • Zaorsky NG, Yamoah K, Thakur ML, Trabulsi EJ, Showalter TN, Hurwitz MD, Dicker AP, Den RB. A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer. Future Oncol. 2014 Feb;10(3):457-474. Pubmedid: 24559451.
  • Yamoah K, Zaorsky NG, Siglin J, Shi W, Werner-Wasik M, Andrews DW, Dicker AP, Bar-Ad V, Liu H. Spine Stereotactic Body Radiation Therapy Residual Setup Errors and Intra-Fraction Motion Using the Stereotactic X-Ray Image Guidance Verification System. Int J Med Phys Clin Eng Radiat Oncol. 2014 Feb;3(1):1-8. Pubmedid: 29333353. Pmcid: PMC5766040.
  • Zaorsky NG, Doyle LA, Yamoah K, Andrel JA, Trabulsi EJ, Hurwitz MD, Dicker AP, Den RB. High dose rate brachytherapy boost for prostate cancer: a systematic review. Cancer Treat Rev. 2014 Apr;40(3):414-425. Pubmedid: 24231548.
  • Yamoah K, Beecham K, Hegarty SE, Hyslop T, Showalter T, Yarney J. Early results of prostate cancer radiation therapy: an analysis with emphasis on research strategies to improve treatment delivery and outcomes. BMC Cancer. 2013 Jan;13:23. Pubmedid: 23324165. Pmcid: PMC3558339.
  • Yamoah K, Stone N, Stock R. Impact of race on biochemical disease recurrence after prostate brachytherapy. Cancer. 2011 Dec;117(24):5589-5600. Pubmedid: 21692058.
  • Fang L, Wang X, Yamoah K, Chen PL, Pan ZQ, Huang L. Characterization of the human COP9 signalosome complex using affinity purification and mass spectrometry. J Proteome Res. 2008 Nov;7(11):4914-4925. Pubmedid: 18850735. Pmcid: PMC2676908.
  • Yamoah K, Brebene A, Baliram R, Inagaki K, Dolios G, Arabi A, Majeed R, Amano H, Wang R, Yanagisawa R, Abe E. High-mobility group box proteins modulate tumor necrosis factor-alpha expression in osteoclastogenesis via a novel deoxyribonucleic acid sequence. Mol Endocrinol. 2008 May;22(5):1141-1153. Pubmedid: 18218727. Pmcid: PMC2366181.
  • Sun L, Vukicevic S, Baliram R, Yang G, Sendak R, McPherson J, Zhu LL, Iqbal J, Latif R, Natrajan A, Arabi A, Yamoah K, Moonga BS, Gabet Y, Davies TF, Bab I, Abe E, Sampath K, Zaidi M. Intermittent recombinant TSH injections prevent ovariectomy-induced bone loss. Proc Natl Acad Sci U S A. 2008 Mar;105(11):4289-4294. Pubmedid: 18332426. Pmcid: PMC2393772.
  • Yamoah K, Oashi T, Sarikas A, Gazdoiu S, Osman R, Pan ZQ. Autoinhibitory regulation of SCF-mediated ubiquitination by human cullin 1's C-terminal tail. Proc Natl Acad Sci U S A. 2008 Aug;105(34):12230-12235. Pubmedid: 18723677. Pmcid: PMC2519045.
  • Kumar A, Wu H, Collier-Hyams LS, Hansen JM, Li T, Yamoah K, Pan ZQ, Jones DP, Neish AS. Commensal bacteria modulate cullin-dependent signaling via generation of reactive oxygen species. Embo J. 2007 Oct;26(21):4457-4466. Pubmedid: 17914462. Pmcid: PMC2063476.
  • Gazdoiu S, Yamoah K, Wu K, Pan ZQ. Human Cdc34 employs distinct sites to coordinate attachment of ubiquitin to a substrate and assembly of polyubiquitin chains. Mol Cell Biol. 2007 Oct;27(20):7041-7052. Pubmedid: 17698585. Pmcid: PMC2168909.
  • Abe E, Sun L, Mechanick J, Iqbal J, Yamoah K, Baliram R, Arabi A, Moonga BS, Davies TF, Zaidi M. Bone loss in thyroid disease: role of low TSH and high thyroid hormone. Ann Ny Acad Sci. 2007 Nov;1116:383-391. Pubmedid: 18083940.
  • Sun L, Peng Y, Zaidi N, Zhu LL, Iqbal J, Yamoah K, Wang X, Liu P, Abe E, Moonga BS, Epstein S, Zaidi M. Evidence that calcineurin is required for the genesis of bone-resorbing osteoclasts. Am J Physiol Renal Physiol. 2007 Jan;292(1):F285-F291. Pubmedid: 16968888.
  • Gazdoiu S, Yamoah K, Wu K, Escalante CR, Tappin I, Bermudez V, Aggarwal AK, Hurwitz J, Pan ZQ. Proximity-induced activation of human Cdc34 through heterologous dimerization. Proc Natl Acad Sci U S A. 2005 Oct;102(42):15053-15058. Pubmedid: 16210246. Pmcid: PMC1242854.
  • Yamoah K, Wu K, Pan ZQ. In vitro cleavage of Nedd8 from cullin 1 by COP9 signalosome and deneddylase 1. Methods Enzymol. 2005;398:509-522. Pubmedid: 16275355.
  • Pan ZQ, Kentsis A, Dias DC, Yamoah K, Wu K. Nedd8 on cullin: building an expressway to protein destruction. Oncogene. 2004 Mar;23(11):1985-1997. Pubmedid: 15021886.
  • Wu K, Yamoah K, Dolios G, Gan-Erdene T, Tan P, Chen A, Lee CG, Wei N, Wilkinson KD, Wang R, Pan ZQ. DEN1 is a dual function protease capable of processing the C terminus of Nedd8 and deconjugating hyper-neddylated CUL1. J Biol Chem. 2003 Aug;278(31):28882-28891. Pubmedid: 12759363.